Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients
- 1 June 2008
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 33 (3), 307-314
- https://doi.org/10.1111/j.1365-2710.2008.00898.x
Abstract
5-fluorouracil (5-FU) is still a widely used anticancer drug. More than 85% of the 5-FU administered is catabolized by dihydropyrimidine dehydrogenase (DPD) in the liver. However, mutations in the DPD gene have been found to be associated with low DPD activity causing severe complications. The purpose of this study was to determine the mutation frequency of four exons in Chinese cancer patients and the relationship between genotype and DPD activity. Samples from 142 cancer patients were investigated in this study. The DPD activity was determined by reversed-phase HPLC. Exons 2, 13, 14 and 18 were amplified by polymerase chain reaction (PCR), sequenced and analysed from both sense and antisense directions. Nonparametric one-sample Kolmogorov-Smirnov test was used for distribution analysis; two independent samples t-test and one-way anova was performed for two groups and three groups analyses, respectively. Plasma-DPD activities in the 142 cancer patients followed a Gaussian distribution. The mean plasma-DPD activity in women was lower than that in men (P = 0.006). Four mutations, 85T>C(DPYD*9A), 1627A>G(DPYD*5), 1896T>C and 2194G>A(DPYD*6), were found in the 142 cancer patients. The following mutations reported by others were not detected: 61C>T, 62G>A, 74A>G, 1601G>A(DPYD*4), 1679T>G(DPYD*13), 1714C>G, 1897delC(DPYD*3) and IVS 14 + 1G>A. No significant correlation was found between three mutations [85T>C(DPYD*9A), 1627A>G (DPYD*5) and 1896T>C], and DPD activity was found. No clear correlation between the mutations studied and DPD activity could be established in this study. However, larger-scale prospective studies are needed to better assess the reported genotype-phenotype correlations.Keywords
This publication has 28 references indexed in Scilit:
- Methylation of the DPYD Promoter: An Alternative Mechanism for Dihydropyrimidine Dehydrogenase Deficiency in Cancer PatientsClinical Cancer Research, 2005
- Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer CellsClinical Cancer Research, 2004
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Pharmacogenomics: Unlocking the Human Genome for Better Drug TherapyAnnual Review of Pharmacology and Toxicology, 2001
- PharmacogeneticsClinical Pharmacokinetics, 2000
- Regulation of Dihydropyrimidine Dehydrogenase and Pyrimidine Nucleoside Phosphorylase Activities by Growth Factors and Subsequent Effects on 5‐Fluorouracil Sensitivity in Tumor CellsJapanese Journal of Cancer Research, 2000
- Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?European Journal of Cancer, 2000
- A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated MetabolitesJournal of Liquid Chromatography & Related Technologies, 1997
- Dihydropyrimidine dehydrogenase activity in cancer patientsEuropean Journal of Cancer, 1993
- Genetic and environmental factors causing variation in drug responseMutation Research - Reviews in Mutation Research, 1991